Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras

Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes

(2015) Frank A. Sinicrope et al.   GASTROENTEROLOGY

Chlorinated Water Modulates the Development of Colorectal Tumors with Chromosomal Instability and Gut Microbiota in Apc-Deficient Mice

(2015) Tatsunari Sasada et al.   PLoS One

ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials

(2014) M. J. Sorich et al.   ANNALS OF ONCOLOGY

Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of Apc and activation of mutant Kras

(2014) Alexander J. Byun et al.   CANCER LETTERS

Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer

(2014) Marta Schirripa et al.   INTERNATIONAL JOURNAL OF CANCER

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

(2014) Lee S. Schwartzberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of 18F-FDG Accumulation in Colorectal Cancer Cells with Mutated KRAS

(2014) M. Iwamoto et al.   JOURNAL OF NUCLEAR MEDICINE

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Understanding Phenotypic Variation in Rodent Models with Germline Apc Mutations

(2013) M. Zeineldin et al.   CANCER RESEARCH

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

(2013) M. Peeters et al.   CLINICAL CANCER RESEARCH

What are the best routes to effectively model human colorectal cancer?

(2013) Madeleine Young et al.   Molecular Oncology

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

(2011) Cecily P. Vaughn et al.   GENES CHROMOSOMES & CANCER

CDX2 Regulates Multidrug Resistance 1 Gene Expression in Malignant Intestinal Epithelium

(2010) Y. Takakura et al.   CANCER RESEARCH

The Chromosomal Instability Pathway in Colon Cancer

(2010) Maria S. Pino et al.   GASTROENTEROLOGY

Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment

(2010) K. E. Hung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutated K-rasAsp12promotes tumourigenesis inApcMinmice more in the large than the small intestines, with synergistic effects between K-rasandWntpathways

(2009) Feijun Luo et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Regulation of Uptake of 18F-FDG by a Follicular Human Thyroid Cancer Cell Line with Mutation-Activated K-Ras

(2009) O. Prante et al.   JOURNAL OF NUCLEAR MEDICINE

Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells

(2009) J. Yun et al.   SCIENCE

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

(2008) Kevin M Haigis et al.   NATURE GENETICS

Generating somatic mosaicism with a Cre recombinase–microsatellite sequence transgene

(2008) Aytekin Akyol et al.   NATURE METHODS